Antibody-drug conjugate · Kills target cells, directed at protein tyrosine kinase 7 (PTK7) · developed by Whitehawk Therapeutics
HWK-007 is an antibody-drug conjugate that binds PTK7, a tumor-associated antigen overexpressed on various cancer cells, and carries an undisclosed cytotoxic payload. After binding and internalization, the payload induces apoptosis in PTK7-overexpressing tumor cells. It is being studied in solid tumors, including endometrial, ovarian and non-small cell lung cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07444814 | Phase 1 | Endometrial Cancer | Recruiting | WHWK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial CancerNon-squamous EGFR Wt NSCLCOvarian CancerOvarian Cancer MetastaticOvarian Cancer Metastatic RecurrentPlatinum Resistant Ovarian CancerPROC
Updated Nov 1, 2026. Something wrong or missing? Report it on the WHWK page.
See WHWK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
WHWK catalysts and pipeline →